Amgen drug shows high response rate in small lung and colon cancer trial
An experimental Amgen Inc drug that targets a specific genetic mutation significantly reduced tumor size in half of evaluated patients with advanced lung cancer in a small, early-stage trial, researchers said on Monday, sending the U.S. biotechnology company's share up nearly 6 percent.
from Reuters: Health News https://reut.rs/2KoVgmk
http://bit.ly/2zwRqiM